000 06041nam a22004095i 4500
999 _c88287
_d88287
_x1
001 88287
003 ES-MaUEC
005 20230207040630.0
007 cr nn 008mamaa
008 161114s2016 ne | s |||| 0|eng d
020 _a9789402408447
024 7 _a10.1007/978-94-024-0844-7
_2doi
040 _aES-MaUEC
050 4 _aRS431.A64
_bK56 2016 EB
100 1 _aKim, Kyu-Won
_9101933
_0Local
245 1 0 _aCancer drug discovery :
_bscience and history
_cby Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim
260 _aDordrecht
_bSpringer
_c2016
300 _a1 recurso en línea (XVII, 276 p.)
_b138 ilustraciones, 134 ilustraciones en color
336 _aTexto (visual)
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
505 0 _aPart {u2160}. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1{u2002}Characteristics of cancer cells -- 1.2{u2002}Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part {u2161}. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1{u2002}A historical background of cancer chemotherapy -- 3.2{u2002}Development of the anticancer drug screening systems -- 3.3{u2002}Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4.{u2002}Alkylating Anticancer Drugs -- 4.1{u2002}Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1{u2002}Plant-derived anticancer drugs -- 6.2{u2002}Anticancer antibiotics -- 7.{u2002}Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1{u2002}Immunotherapeutic anticancer drugs -- 7.2{u2002}Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9.{u2002}Molecular Targeted Anticancer Drugs -- 9.1{u2002}Tretinoin (all-trans retinoic acid, ATRA) -- 9.2{u2002}Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4{u2002}HER2 inhibitors -- 9.5{u2002}Angiogenesis inhibitors -- 9.6{u2002}Other kinase inhibitors -- 9.7{u2002}mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9{u2002}Epigenetic anticancer drugs -- 9.10{u2002}Proteasome inhibitors -- 9.11{u2002}Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part {u2162}. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs
520 _aThis book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the {u2018}cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer
650 0 7 _aAntineoplásicos
_xUso terapeútico
_9405304
_0LocalZ
_2embne
650 0 7 _aCáncer
_xTratamiento
_9174085
_0LocalZ
_2embne
650 7 _aCáncer
_xInvestigación
_0comprobar BNE19901364217
_2embne
_9182523
700 1 _aRoh, Jae Kyung
_9101934
_0Local
700 1 _aWee, Hee-Jun
_9101935
_0Local
700 1 _aKim, Chan
_9101936
_0Local
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-94-024-0844-7zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901 _ai9789402408447
907 _a.b1298291x
_b10-10-17
_c08-03-17
942 _2lcc
_cLE
945 _aRS431 .A64 K56 2016 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i1160475x
_z06-04-17
988 _aEBOOK, EBSPRINGER
998 _am
_a_alco
_a_vill
_b19-06-17
_cm
_dz
_eb
_feng
_gne
_h0